Epidermal growth factor receptors (EGFR) are a group of receptor tyrosine kinase (RTK) that plays a major role in cell proliferation, survival and differentiation. In most of the cancer, EGFR are amplified and overexpressed, due to dysregulation, resulting in cancer development.
Download the sample report @ https://www.pharmaproff.com/request-sample/1208
EGFR inhibitors therapies have shown improvement by inhibiting receptor signalling and enhancing the effects of radiation therapy and conventional chemotherapy with their anti-tumor activity. Cetuximab, Panitumumab, Erlotinib and Afatinib are some of the major marketed drugs as anti-EGFR therapies for the treatment of colorectal cancer, head and neck cancer and non-small cell lung cancer.
Get the detailed analysis @ https://www.pharmaproff.com/report/egfr-antagonists-therapeutics
Daiichi Sankyo Co., Ltd. is in the process of developing Nimotuzumab as a humanized monoclonal antibody which acts as an EGFR inhibitor for the treatment of gastric cancer. Some of the other companies having pipeline of EGFR inhibitors include Daiichi Sankyo Co., Ltd., Shionogi & Co. Ltd., AstraZeneca PLC, and Amgen Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.
Healthcare Research Report 